Plasmid growth hormone releasing hormone therapy in healthy and laminitis-afflicted horses-evaluation and pilot study.

The research paper discusses a pilot study on the effects of a treatment method using growth hormone releasing hormone (GHRH) on both healthy horses and those suffering from laminitis, a debilitating disease common in horses. The reported outcomes indicate that this therapy improved the health and physique of the subjects and could potentially be suitable for treating long-term conditions in large mammals, providing preliminary evidence in the realm of gene therapeutic treatments for human diseases like Raynaud’s syndrome and arthritis.

Methods

• The researchers used in vivo electroporation, a technique that increases the effectiveness of plasmid-mediated therapies. In this case, the therapy administered was a plasmid that expressed the growth hormone releasing hormone (GHRH).
• The method involved a single intramuscular injection, followed by electroporation, of 2.5 mg of the GHRH-expressing plasmid.
• The procedure’s impacts were observed in two groups of horses – six healthy horses and two horses that suffered from chronic laminitis, a vascular condition often associated with arthritis. The study followed the progress of the subjects for a period of 6 months.

Results

• In the healthy horses examined in the study, the researchers observed an increase in body mass by day 180 as compared to the baseline, with the difference being statistically significant.
• A significant increase was also seen in the erythrocyte (red blood cells) production, measured in terms of hematocrit, red blood cells count, and hemoglobin levels.
• Another significant finding was the 7% increase in IGF-I levels by day 120.
• The laminitis-afflicted horses that received the treatment showed weight gain compared to the control horses (which did not receive the treatment). By the end of the 6-month period, these treated horses were assessed to be pasture sound. These horses also showed visible physical and radiographic improvements, including reduced inflammation and decreased lameness.

Conclusions

• The findings of this exploratory study point towards the potential of plasmid therapy, delivered through electroporation, in treating chronic conditions in large mammals, such as horses.
• The positive effects of the treatment open up possibilities for its application in gene therapeutic treatments for human ailments such as Raynaud’s syndrome and arthritis. However, it’s crucial to remember that these are preliminary findings, and further studies are required to ascertain the full potential and applicability of the method.